- Home
- EVV vs SPRY Comparison
EVV vs SPRY Comparison
Compare EVV & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVV
- SPRY
- Stock Information
- Founded
- EVV 2003
- SPRY 2015
- Country
- EVV United States
- SPRY United States
- Employees
- EVV N/A
- SPRY N/A
- Industry
- EVV Finance/Investors Services
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- EVV Finance
- SPRY Health Care
- Exchange
- EVV Nasdaq
- SPRY Nasdaq
- Market Cap
- EVV 1.2B
- SPRY 1.4B
- IPO Year
- EVV N/A
- SPRY N/A
- Fundamental
- Price
- EVV $9.89
- SPRY $11.18
- Analyst Decision
- EVV
- SPRY Strong Buy
- Analyst Count
- EVV 0
- SPRY 4
- Target Price
- EVV N/A
- SPRY $24.00
- AVG Volume (30 Days)
- EVV 323.7K
- SPRY 1.1M
- Earning Date
- EVV 01-01-0001
- SPRY 11-13-2024
- Dividend Yield
- EVV 9.66%
- SPRY N/A
- EPS Growth
- EVV N/A
- SPRY N/A
- EPS
- EVV N/A
- SPRY N/A
- Revenue
- EVV N/A
- SPRY $2,568,000.00
- Revenue This Year
- EVV N/A
- SPRY $95,526.66
- Revenue Next Year
- EVV N/A
- SPRY $275.98
- P/E Ratio
- EVV N/A
- SPRY N/A
- Revenue Growth
- EVV N/A
- SPRY 8460.00
- 52 Week Low
- EVV $8.52
- SPRY $5.10
- 52 Week High
- EVV $10.07
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- EVV 33.06
- SPRY 32.88
- Support Level
- EVV $9.76
- SPRY $10.63
- Resistance Level
- EVV $10.30
- SPRY $14.50
- Average True Range (ATR)
- EVV 0.11
- SPRY 0.82
- MACD
- EVV -0.05
- SPRY -0.20
- Stochastic Oscillator
- EVV 20.63
- SPRY 14.26
About EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest
Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund may, as a secondary objective, also seek capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure among others.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.